RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)

Inclusion Criteria:

• See NCT06404086 for RECOVER-SLEEP: Platform Protocol level inclusion criteria which applies to this appendix

Exclusion Criteria:

• See NCT06404086 for RECOVER-SLEEP: Platform Protocol level exclusion criteria which applies to this appendix (or sub-study)

Additional Appendix A (Hypersomnia) Level Exclusion Criteria:

1. Self-reported sleep duration <6 hours per night

2. Poorly controlled hypertension (systolic blood pressure ≥140 or diastolic bloodpressure ≥90 mmHg)

3. Moderate to severe hepatic impairment (ie, Child-Pugh class B or C)*

4. Known estimated glomerular filtration rate <30 mL/min/1.73 m2 and/or chronicdialysis*

5. Recent myocardial infarction (<1 year), unstable angina, serious cardiacarrhythmias, or other serious heart problems, at the discretion of the investigator

6. Current use of stimulant or wake-promoting medications, unless a washout ispermitted

7. Regular use of prescribed hypnotics for sleep (≥3 times per week); washout period ispermitted.

• characterized by the screening labs: coagulation panel and CMP w/LFTs

MODAFINIL EXCLUSION CRITERIA

1. Modafinil can affect drug metabolism given its effect on enzymes such as CYP3A4 andCYP2C19. To assess for drug interactions, investigators should use the Lexicomp DrugInteractions System that is available at most institutions. o If the search yields "D" - Consider Modifying Therapy or "X" - Avoid Combination,then the ACTION is to exclude the potential participant. An important example of this is steroid hormonal contraceptives.

• If the search yields "C" - Monitor Therapy, then discuss with site PIs on acase-by-case basis.

• If the search yields "A" - No Known Interaction or "B" - No Action Needed, thenproceed to screen/include the potential participant.

2. Known severe left ventricular hypertrophy, mitral valve prolapse

SOLRIAMFETOL EXCLUSION CRITERIA

1. Concurrent treatment with a monoamine oxidase inhibitor (MAOI) or use of an MAOIwithin the preceding 14 days

2. Current use of dopaminergic drugs